Advaxis receives Orphan Drug Designation from FDA for cervical cancer drug
ADXS-HPV is Advaxis’ lead immunotherapy drug candidate designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.